Curaleaf (OTCMKTS:CURLF - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02, Zacks reports. Curaleaf had a negative return on equity of 0.88% and a negative net margin of 2.62%.
Curaleaf Stock Up 10.5%
CURLF traded up $0.96 on Tuesday, reaching $10.12. 441,775 shares of the stock were exchanged, compared to its average volume of 145,527. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.52. The company's 50-day moving average price is $9.55 and its 200 day moving average price is $8.30. Curaleaf has a fifty-two week low of $5.40 and a fifty-two week high of $15.15.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on CURLF. UBS Group set a $6.00 price objective on Curaleaf in a research report on Monday, October 5th. Citigroup restated a "buy" rating on shares of Curaleaf in a research note on Thursday, August 6th. Finally, Zacks Research cut shares of Curaleaf from a "strong-buy" rating to a "hold" rating in a report on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Curaleaf has a consensus rating of "Buy" and an average target price of $6.00.
Read Our Latest Report on Curaleaf
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc is a cannabis company that cultivates, processes, distributes and sells cannabis products for medical and adult-use markets. Its portfolio includes cannabis flower, pre-rolls, vaporizers, concentrates, edibles, tinctures, capsules, topicals and other wellness products, offered under brands such as Curaleaf, Select and Grassroots.
The company serves customers through a network of retail dispensaries and wholesale channels in regulated U.S. cannabis markets. Its operations include cultivation and manufacturing facilities as well as dispensaries, with products distributed in multiple states where medical or adult-use cannabis is permitted.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.